AXN 20x
Alternative Names: AXN-20xLatest Information Update: 03 Mar 2023
At a glance
- Originator AXONIS Therapeutics
- Class Neuroprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Neurodegenerative disorders
Most Recent Events
- 03 Mar 2023 Feedback incorporated
- 13 Jan 2023 Early research in Neurodegenerative disorders in United Kingdom (unspecified route) (AXONIS Therapeutics pipeline, January 2023)